-
5 days ago | 
businessandamerica.com | Virginia Kaklamani
Clinical Brief: Elacestrant Subgroup Benefits and Safety Profile Main Discussion Topics: Efficacy across different disease sites (bone-only versus visceral) Impact of tumor burden (multiple sites of metastasis) Co-mutation status (PIK3CA, p53) and treatment efficacy Safety profile focusing on gastrointestinal (GI) tolerability and lipid monitoring FDA recommendation for lipid profile monitoring requirements Key Points for Physicians: Elacestrant efficacy maintained in visceral disease and...
-
5 days ago | 
businessandamerica.com | Virginia Kaklamani
Clinical Brief: Second-Line Treatment Decision Framework Main Discussion Topics: Integration of patient factors in treatment selection Balance between efficacy and quality-of-life considerations Practical considerations: insurance, copays, administration route Sequential versus concurrent treatment strategies Role of shared decision-making in complex treatment landscape Key Points for Physicians: Treatment selection requires balance of clinical trial data with patient-specific factors...
-
1 week ago | 
curetoday.com | Virginia Kaklamani |Megan Kruse
Author(s):,Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.
-
1 week ago | 
curetoday.com | Virginia Kaklamani |Megan Kruse
Author(s):,Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.
-
3 weeks ago | 
onclive.com | Virginia Kaklamani
CommentaryVideoApril 18, 2025Author(s):Fact checked by:,Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.
-
2 months ago | 
onclive.com | Virginia Kaklamani
CommentaryPodcastMarch 10, 2025Author(s):Fact checked by:,Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm. Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.
-
Feb 10, 2025 | 
cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani
February 10, 2025By Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective.
-
Feb 10, 2025 | 
cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani
February 10, 2025By Panelists discuss how locally advanced triple-negative breast cancer (LATNBC) is an aggressive breast cancer subtype characterized by absence of estrogen receptor, progesterone receptor, and HER2 protein expression. It presents with large tumors and/or extensive lymph node involvement without distant metastasis. Treatment typically involves neoadjuvant chemotherapy followed by surgery and radiation. Related Content Related Content
-
Feb 10, 2025 | 
cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani
February 10, 2025By Panelists discuss how the approach to metastatic disease focuses on systemic therapy, as cancer has spread beyond its primary site. Treatment typically combines targeted therapy, immunotherapy, chemotherapy, and/or hormonal therapy based on cancer type and molecular profile. Goals shift toward extending survival, controlling symptoms, and maintaining quality of life rather than cure. Regular monitoring of treatment response and adverse effects guides ongoing care decisions.
-
Feb 10, 2025 | 
cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani
February 10, 2025By Panelists discusses how triple-negative breast cancer (TNBC) treatment toxicities require careful monitoring and management. Common adverse effects include fatigue, nausea, hair loss, neuropathy from chemotherapy, and radiation-induced skin changes. Health care teams employ preventive strategies, dose modifications, and supportive care to minimize complications while maintaining treatment efficacy. Related Content Related Content
